



Proto-hormones of adipose 
tissue, such as leptin, adiponec-
tin, as well as proinflammatory 
cytokine IL-6, play an important 
role in the progression of arterial 
hypertension in obesity. 
Adiponectin is a protein hor-
mone, which is mainly synthe-
sized in the adipose tissue; its 
expression is higher in subcuta-
neous than in visceral fat [1]. It 
affects carbohydrate and lipid 
metabolism, participates in the 
regulation of blood pressure, pre-
vents inflammatory processes in 
the endothelium of blood vessels, 
reduces the damage due to isch-
emia and reperfusion of the car-
diac muscle and also reduces liver 
fibrosis [2, 3]. The level of adi-
ponectin is significantly reduced 
in case of obesity, insulin resis-
tance, type 2 diabetes, hypergly-
cemia and many cardiovascular 
diseases (myocardial infarction, 
acute coronary syndrome, isch-
emic heart disease) [4]. 
Leptin is a product of the 
expression of the obesity gene, 
a protein-producing hormone, 
synthesized by cells of white and 
brown fatty tissue, in a lesser 
extent – in the skeletal muscle, 
stomach and placenta [5]. Ac-
cording to literature, leptin has 
antisteatogenic effects, regulates 
and controls intracellular homeo-
stasis of glucose and free fatty 
acids, prevents the development 
of glucotoxicity and lipotoxicos- 
is [6]. Other authors established 
the profibrogenic effect of lep- 
tin [7]. Hyperleptinemia stimu-
lates the development of NAFLD, 
in particular, fibrosis [8]. 
According to many studies, 
IL-6 is associated with the develop-
ment of metabolic disorders [9, 10]. 
It is produced by fibroblasts, en-
dothelial cells, monocytes and adipocytes, it is also character-
ized by multifactoriality and a wide range of biological effects. 
The aim of the study was to assess the status of the detoxi-
fying function of liver and analyze changes in the level of leptin, 
adiponectin and IL-6 in patients with arterial hypertension in 
combination with obesity and non-alcoholic fatty liver disease 
in accordance with the degree of activity of non-alcoholic ste-
atohepatitis and myocardial mass index.
2. Materials and methods
The study involved 50 patients with stage II–III AH who 
were selectively hospitalized in Lviv City Clinical Emergency 
Hospital (Lviv, Ukraine) for the period from 2018–2019. The 
patients, who underwent clinical and diagnostic examination, 
28 (56 %) were women of a mean 
age of 58.2±0.97. All patients un-
derwent anthropometric, general 
clinical, laboratory (blood lipid 
profile) and instrumental diag- 
nostics (electrocardiography, echo- 
cardiography, ultrasonography, 
13C-metacetin breath test, ELISA 
(adiponectin, leptin, IL-6). Pa-
tients’ height and weight were 
measured, the body mass index 
was calculated according to Que-
telet formula.
The level of office blood pres-
sure was measured on the same 
arm in a sitting position at in-
tervals of 2 min thrice in the 
morning; an average of 3 mea- 
surements was calculated. The 
heart rate was evaluated after 
the second measurement. AH 
was established according to the 
standards of its diagnostics and 
treatment and in accordance 
with the recommendations of 
the Ukrainian Association of 
Cardiology, the European So-
ciety of Hypertension and the 
European Society of Cardiolo-
gy (ESH/ESC). While choosing 
the treatment strategy and fol-
low-up plan, we also referred to 
the current orders and protocols 
of MHC of Ukraine, ESH/ESC 
recommendations, guidelines of 
American Gastroenterology As-
sociation (AGA) and American 
Association for the Study of Liver 
Diseases (AASLD) [11]. 
Informed consent to partic-
ipate in the study was obtained 
from all patients (protocol of the 
Commission on Bioethics No. 1/18 
of 15.01.2018).
To identify the ultrasonogra- 
phic signs of non-alcoholic stea- 
tohepatitis, all individuals under- 
went ultrasonography (USG) of 
internal organs with particular at-
tention paid to an increase in the 
liver size, density of its parenchyma, diffuse homogenous increase 
in echogenicity, distal shadowing and increase in the diameter of 
the portal vein. Fatty liver was determined in case of an increased 
liver size, diffuse homogeneous echogenicity and appearance of 
distal shadowing. To determine the functional state of microso-
mal enzyme systems of hepatocytes, we performed 13C-metacetin 
breath test. This test provides an opportunity to non-invasively 
evaluate the percentage of functioning hepatocytes, classify liver 
failure into cirrhotic and non-cirrhotic type and establish its degree 
according to the Child-Pugh criteria. The sensitivity and speci-
ficity of 13C-metacetin breath test is >90 % [12, 13]. The infrared 
spectroscope IRIS (Wagner, Germany) analyzed the air samples. 
The results of 13C-metacetin breath test evaluated the an-
titoxic function of the liver, determining its metabolic capac-
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Abstract: The research estimates the state of liver detoxifying 
function and analyzes the changes in the levels of leptin, adi-
ponectin and interleukin-6 in patients with arterial hyperten-
sion in combination with obesity and non-alcoholic fatty liver 
disease.
Aim. The aim of the study is to evaluate levels of proto-hor-
mones adipose tissue, interleukin-6 and indicators of detoxify-
ing function of the liver in patients with hypertension and obe-
sity combined with non-alcoholic fatty liver disease (NAFLD).
Materials and methods. The study involved patients with arte-
rial hypertension combined with obesity and NAFLD. All pa-
tients underwent anthropometric, general clinical, laboratory 
(blood lipid profile) and instrumental diagnostics (electrocar-
diography, echocardiography, ultrasonography, 13C-metace-
tin breath test, ELISA (adiponectin, leptin, IL-6). The patients’ 
height and weight were measured, the body mass index was 
calculated according to standard formulas.
Results. Patients with arterial hypertension combined with 
obesity and NAFLD at the stage of steatohepatitis showed an 
increase in the levels of leptin and IL-6 and a decrease in the 
level of adiponectin. This group also revealed a moderate de-
crease in liver detoxifying function, as indicated by the results 
of 13C-MBT due to a 46.7 % decrease in the metabolic rate 
and a decrease in cumulative doses of CUM40 by 40 % and 
CUM120 by 46.8 %, respectively.
Conclusions. The elevated levels of leptin and IL-6 and low-
ered adiponectin levels can be used to determine the degree of 
activity of non-alcoholic steatohepatitis and predict the course 
of NAFLD in combination with hypertension and obesity.
An increased level of leptin and IL-6 and a low level of adi-
ponectin in patients with such a comorbid pathology lead to 
an increase in the left ventricular myocardial mass index and 
aggravate the course of arterial hypertension.
Keywords: arterial hypertension, obesity, non-alcoholic steato-
hepatitis, leptin, adiponectin, IL-6, 13C-metacetin breath test.
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ity and metabolic rate of hepatocytes at 40 and 120 minutes. 
This method makes it possible to determine the proportion of 
functioning hepatocytes, as well as differentiate steatosis from 
steatohepatitis and fibrosis.
Echocardiography was performed in the M- and B-modes 
using the standard Siemens Acuson S3000 (Germany) ultraso-
nographic apparatus. According to the results of the echocar-
diogram, the mass of the myocardium (MM) (according to the 
Penn-Convention formula), the index of the myocardial mass 
(IMM) and the relative thickness of the myocardium (RTM) 
were calculated.
The level of adiponectin, level and IL-6 was evaluated using 
ELISA. All immuno-enzymatic methods were performed using 
the “Stat Fax 303 plus” analyzer (Awareness Technology, USA). 
The results were processed statistically using Student’s test, 
Pearson correlation analysis with “Microsoft Excel” software.
3. Results
After the clinical examination and USG, 50 patients were 
selected to confirm the diagnosis of non-alcoholic steatohep-
atitis using 13C-metacetin breath test. The control group was 
made up of 10 presumably healthy persons. According to the 
results of the 13C-metacetin breath test, the metabolic rate was 
found in the range from 4.3 (%13C/h) to 18.5 (%13C/h), which 
averaged (13.66±0.39) (%13C/h). This was significantly lower by 
46.7 % compared with the control group (p<0.01). The cumula-
tive dose for 40 minutes (CUM40) was (7.28±0.26) (%13C) which 
decreased by 40 % (p<0.01), the cumulative dose for 120 minutes 
(CUM120) – (12.69±0.57) (%13C) decreased by 46.8 % (p<0.01) 
compared to the control group (Table 1). 
Among the patients who underwent the respiratory test, 
the expressed significant signs of steatohepatitis were detected 
in 21 (42.0 %) patients, while in the remaining 29 (58.0 %) the 
subjects, signs of steatosis transition into steatohepatitis were 
observed. Criteria for reliable signs of steatohepatitis included 
simultaneous changes of all 3 indicators, any 2 detected changes 
(metabolic rate and/or CUM40 and/or CUM120) were consid-
ered to be equivocal signs of steatohepatitis.
Table 1
Results of metacetin 13C-breath test




(Dose/h %) 25.63±1.36 13.66±0.39*
CUM40 (%) 12.10±0.50 7.28±0.26*
CUM120 (%) 23.88±0.73 12.69±0.57*
Note: *– р<0.01 compared with the control group
Results of metacetin 13C-breath test indicated the presence 
of fatty liver infiltration in the patients as provoked by obesity, 
which, in turn, leads to changes in the indicators of functional 
state of the liver. Thus, 13C-metacetin breath test was able to 
reliably establish a reduced function of hepatocytes and confirm 
the diagnosis of non-alcoholic steatohepatitis. On the basis of 
these data, patients were divided into groups with a pronounced 
decrease in the activity of hepatocytes and with a moderate de-
crease in the activity of hepatocytes.
The results of the study showed that leptin levels in patients 
with hypertension in combination with obesity and non-alco-
holic fatty liver disease (NAFLD) ranged from 9.7 to 90.8 ng/ml 
and averaged 41.85±3.34 ng/ml. An increase in the level of leptin 
above the reference values was found in 80 % of the examined 
patients, indicating a metabolic process disorder with combined 
pathology.
The level of IL-6 in patients with hypertension in combi-
nation with obesity and NAFLD ranged from 1.8 to 25 pg/ml 
and averaged (9.12±0.73) pg/ml. An increase in the level of IL-6 
above the reference values was found in 84.0 % of the examined 
patients, indicating the development of subclinical inflamma-
tion with comorbidity.
The adiponectin level ranged from 6.20 to 24.68 μg/ml 
(averaged 16.02±0.57 μg/ml). The decrease in adiponectin levels 
below the reference values was found in 88.0 % of the examined 
patients, indicating an inadequate protective activity of the 
body in hypertension combined with obesity and NAFLD.
As seen in Table 2, the level of leptin in patients with 
non-alcoholic steatohepatitis (NASH) with pronounced de-
crease in hepatocyte activity in the 13C-metacetin breath test 
index was 48.86±4.51 ng/ml and significantly exceeded the 
similar figure twice as compared to those with non-alcoholic 
steatohepatitis with moderate decrease in hepatocyte activi- 
ty ((24.15±2.36) ng/ml) (p<0.05). 
The level of adiponectin in patients with a combined pathol-
ogy associated with a moderate hepatocyte activity decreased 
reaching (19.14±0.36) μg/ml on average and was significantly 
higher than that of patients with non-alcoholic steatohepatitis 
with a pronounced decrease in hepatocyte activity by 48.4 %; 
the median values was (12.90±0.56) μg/ml (p<0.01), (Table 2). 
Indicators of IL-6 in patients with combined a pathology and a 
pronounced decrease in hepatocyte activity were 1.7 times high-
er compared to the respective indices in patients with non-al-
coholic steatohepatitis and a moderate decrease of hepatocyte 
activity (p<0.01) (Table 2).
Table 2
Levels of leptin, adiponectin and interleukin-6 depending on the 
activity of the inflammatory process
Indexes
NASH with  
a moderate decrease 
in the activity of  
hepatocytes  
(n=27)
NASH with  
pronounced decrease 









Note: * – р<0.05 among a group of patients with non-alcoholic steatohep-
atitis with a moderate decrease in hepatocyte activity and a pronounced 
decrease in the activity of hepatocytes; ** – р<0.01 among a group of 
patients with non-alcoholic steatohepatitis with a moderate and severe 
decrease in the activity of hepatocytes
In our opinion, an elevated level of leptin and IL-6 and low-
ered adiponectin levels can be used to determine the degree of 
activity of non-alcoholic steatohepatitis and predict the course 
of NAFLD in combination with hypertension and obesity.
The level of leptin in patients with hypertension in combi-
nation with obesity and NAFLD with an index of myocardial 
mass of less than 100 g/m2 was (34.04±3.22) ng/ml on average 
and exceeded a similar figure in case of an index of myocardial 




Levels of leptin, adiponectin and IL-6 depending on the mass 
index of myocardium
Indexes
The myocardial mass 
index is less than  
100 g/m2  
(n=37)
The myocardial mass 
index is more  








Note: *– р<0.05 – probability between groups
The adiponectin level at an IMM less than 100 g/m2 reached 
16.42±0.72 μg/ml on average and was 1.08 times higher than 
with an IMM greater than 100 g/m2 (p>0,05). The level of 
IL-6 was 12.7 % higher with an IMM greater than 100 g/m2 
compared with a similar index in the IMM of less than 
100 g/m2 (p>0.05), (Table 3). In women, the average level of 
leptin was (45.63±4.06) ng/ml and was 1.3 times higher than 
that of men (p<0.05) (Table 4). In women, the average level of 
leptin was (45.63±4.06) ng/ml and was 1.3 times higher than 
that of men (p<0.05) (Table 4).
Table 4
Levels of leptin, adiponectin and IL-6 according to gender 
characteristics





For female – 
0.5–13.8





For female – 11.7
For male – 7.9 16.60±1.26 15.40±0.76
Interleukin-6, 
pg/ml 1.5–7 8.46±0.82 7.98±0.86
Note: * – р<0.05 – probability between groups
In women, the average adiponectin level was (16.60± 
±1.26) μg/ml and was 1.1 times higher than that of men 
(15.40±0.76) μg/ml, but it was not significantly different from 
that of men (p>0.05) (Table 4).
4. Discussion
Thus, according to the results of 13C-metacetin breath 
test, a moderate decrease in the detoxifying function of the 
liver was observed, indicating a decelerated metabolic rate by 
46.7 %, in particular, CUM40 decreased by 40 % and CUM120 
decreased by 46.8 % in hypertensive patients with obesity and 
NAFLD at the stage of steatohepatitis, in comparison with the 
control group.
According to the results of ELISA in patients with hy-
pertension associated with obesity and NAFLD at the stage 
of steatohepatitis, levels of leptin and IL-6 increased while 
levels of adiponectin decreased. The elevated levels of leptin 
and IL-6 and lowered adiponectin levels can be used to deter-
mine the degree of activity of non-alcoholic steatohepatitis 
and predict the course of NAFLD in combination with hy-
pertension and obesity. It was more pronounced in case of a 
significant reduction in the activity of hepatocytes compared 
with a moderate decrease in their activity; this indicates the 
effect of these biologically active compounds on the func-
tional state of the liver.
We established an adverse effect of an increased level of 
leptin and IL-6 and a reduced level of adiponectin upon the 
course of hypertension, which adversely affects the increase of 
IMM in patients with comorbid pathology and aggravates the 
condition and course of this pathology [10, 14].
Limitations of the study. In accordance with the limitations 
of this study, the results can be determined as preliminary. For 
further detailed analysis, we plan to continue this study with a 
large number of patients.
5. Conclusions
The results of the study involving patients with hyperten-
sion and obesity combined with non-alcoholic fatty liver disease 
showed a moderate decrease in the detoxifying function of the 
liver, increased levels of leptin, IL-6 and decreased levels of 
adiponectin.
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